Elevance Health, Inc. (ELV)

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

Ticker
ELV
Exchange
NYSE
Sector
Healthcare
Industry
Healthcare Plans
Market cap
$93.78B
52-week range
$274.84 - $450.69

Valuation

Share price
$400.84 (close of Nov 18, 2026)
P/E (TTM)
18.35x
Price to book
2.09x
Price to free cash flow
14.40x
Enterprise value
$114.19B
Book value per share
$207.27

Price performance

PeriodChange
1 day-7.63%
5 days-6.67%
1 month-6.40%
3 months+0.65%
6 months+1.72%
Year to date+14.35%
1 year+23.51%
3 years-13.42%
5 years-5.88%
10 years+196.15%
All time+1,860.10%

Short interest

As of
Oct 30, 2026
Short % of float
2.36%
Shares short
4.54M
Days to cover
3.26
Change since prior report
-11.53%
Source
FINRA consolidated short interest

Members of Congress who disclosed ELV trades

Gilbert Ray Cisneros · Jared Moskowitz · Lisa McClain · Jefferson Shreve · Robert Bresnahan · Val Hoyle · Alan Armstrong · Dan Newhouse · Markwayne Mullin

Super investors holding ELV

Bill Nygren (Harris Associates LP) · First Eagle Investment (First Eagle Investment Management, LLC) · Seth Klarman (Baupost Group) · Ruane Cunniff (Ruane, Cunniff & Goldfarb L.P.) · Glenn Greenberg (Brave Warrior Advisors, LLC) · Ken Griffin (Citadel) · Yacktman Asset Mgmt (Yacktman Asset Management LP) · Richard Pzena (Pzena Investment Management) · Harry Burn (Sound Shore Management) · Vulcan Value Partners (Vulcan Value Partners, LLC) · Tweedy Browne (Tweedy Browne Company LLC) · Lee Ainslie (Maverick Capital LTD)

And 1 other

Profitability and growth

Return on equity
12.86%
Return on assets
4.66%
Net margin
2.84%
Revenue growth
12.49%
Net income growth
-5.32%
Free cash flow growth
-30.27%

Cash flow and balance sheet

Free cash flow yield (TTM)
6.95%
Current ratio
1.47x
Net debt to EBITDA
2.95x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$199.13B
Net income
$5.66B
Earnings per share
$25.28
Interest expense
$1.40B
Shares outstanding
224.00M

Income statement by year

Period endRevenueNet incomeEPS
2025-12-31$199.13B$5.66B$25.28
2024-12-31$177.01B$5.98B$25.81
2023-12-31$171.34B$5.99B$25.38
2022-12-31$156.59B$5.89B$24.56
2021-12-31$138.64B$6.16B$25.26
2020-12-31$121.87B$4.57B$18.23
2019-12-31$104.21B$4.81B$18.81
2018-12-31$92.11B$3.75B$14.53
2017-12-31$90.04B$3.84B$14.70
2016-12-31$84.86B$2.47B$9.39

Margins and returns by year

Period endNet marginReturn on equity
2025-12-312.84%12.86%
2024-12-313.38%14.44%
2023-12-313.49%15.19%
2022-12-313.76%16.22%
2021-12-314.44%17.04%
2020-12-313.75%13.78%
2019-12-314.61%15.17%
2018-12-314.07%13.13%
2017-12-314.27%14.50%
2016-12-312.91%9.84%

Cash and debt by year

Period endCashDebt
2025-12-31$9.49B$30.80B
2024-12-31$8.29B$29.22B
2023-12-31$6.53B$23.25B
2022-12-31$7.39B$22.35B
2021-12-31$4.88B$21.16B
2020-12-31$5.74B$19.34B
2019-12-31$4.94B$17.79B
2018-12-31$3.93B$17.22B
2017-12-31$3.61B$17.38B
2016-12-31$4.08B$14.36B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$3.17B$276.00M
2024-12-31$4.55B$191.00M
2023-12-31$6.76B$289.00M
2022-12-31$7.25B$264.00M
2021-12-31$7.28B$255.00M
2020-12-31$9.67B$283.00M
2019-12-31$4.98B$294.00M
2018-12-31$2.62B$226.00M
2017-12-31$3.39B$170.00M
2016-12-31$2.69B$165.00M

Dividend history

Most recent payment
Sep 10, 2026
Paid in the last twelve months
$6.87
Payment dateDividend per share
2026-09-10$1.72
2026-06-10$1.72
2026-03-10$1.72
2025-12-05$1.71
2025-09-10$1.71
2025-06-10$1.71
2025-03-10$1.71
2024-12-05$1.63

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-21Sep 2026$4.66
2026-07-15Jun 2026$6.18
2026-04-22Mar 2026$10.68
2026-01-28Dec 2025$3.10
2025-10-21Sep 2025$4.98
2025-07-17Jun 2025$9.16
2025-04-22Mar 2025$11.97
2025-01-23Dec 2024$3.80

Filings and sources

Company website
elevancehealth.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Cigna Group (CI) · CVS Health Corp (CVS) · Humana Inc (HUM) · UnitedHealth Group Inc (UNH) · Centene Corp (CNC) · Molina Healthcare, Inc. (MOH) · Henry Schein Inc (HSIC) · Cardinal Health Inc (CAH)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades